Vilon

Vilon is a synthetic dipeptide (Lys-Glu, KE) bioregulator developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a thymus-derived bioregulator that modulates immune function, particularly T-lymphocyte activity, and has been studied for its anti-aging and immunomodulatory properties in preclinical and Russian clinical research.

Vilon interacts directly with DNA by binding to the GCGC sequence in curved nucleosomal DNA and the TCGA sequence in B-form double-stranded DNA, positioning itself in the minor groove of the DNA helix. This epigenetic interaction modulates gene transcription in thymocytes, T-lymphocytes, and supporting immune cells without covalently altering the DNA sequence. In aged immune tissue, Vilon reduces apoptosis in T-helper cells rather than driving proliferation, restoring immune competence through a preservation mechanism. It significantly reduces TNF-α production (by up to 6-fold) and IL-6 release (up to 2.5-fold) in LPS-stimulated peripheral blood mononuclear cells, suggesting broad anti-inflammatory and immunoregulatory effects. Vilon was originally derived from analysis of thymalin, a thymic polypeptide complex.

Russian research from Khavinson's group spanning four decades documents Vilon's immunomodulatory effects in aging animal models and limited human observational studies. Studies demonstrate restoration of thymic T-cell output in elderly subjects, reduction in inflammatory cytokine production, and improvement in lymphocyte proliferative responses. No large randomized controlled trials have been conducted in Western clinical settings. The research base consists primarily of Russian-language publications and animal experiments, with no published human RCTs meeting FDA standards.

Peptides commonly paired with Vilon for synergistic effects.